Craig Crews pioneered PROTAC-based targeted protein degradation and proteasome-directed chemistries. At Yale and as a co‑founder of Arvinas, he bridges biology and medicinal chemistry to design, screen and evaluate degraders and small molecules for oncology and inflammation.